Tempus Enters Multi-Year Strategic Collaboration with Boehringer Ingelheim to Advance its Cancer Pipeline May 21, 2025
IND application for Ph 1 trial of Penetrium™ in combination with docetaxel voluntary withdrawn May 21, 2025
IND cleared for ERAS-0015 and IND submitted for ERAS-4001; Ph 1 monotherapy data for both programs expected in 2026 May 21, 2025
Cellipont Bioservices and Optieum Biotechnologies Partner to Advance cGMP Manufacturing of CAR-T Therapy for Glioblastoma May 13, 2025
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific ADC Program May 6, 2025
Adagene Achieves $3M Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked ADC May 5, 2025
Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals April 30, 2025
FDA clears IND application for VS-7375, Enabling Ph 1/2a Trial in Advanced Solid Tumors April 30, 2025
Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of TCR-NK Therapy ZI-MA4-1 Targeting Solid Tumours April 30, 2025
Veraxa and Voyager to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Gen Cancer Therapies April 30, 2025
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers April 30, 2025
NMPA accepted NDA for zurletrectinib (ICP-723) for patients with advanced solid tumors harboring NTRK gene fusions April 22, 2025
